Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 3/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.58 |
| ▸ | RAB9A | P51151 | 2/20 | 0.58 |
| ▸ | HPGD | P15428 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 2/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | FPR3 | P25089 | 3/20 | 0.51 |
| ▸ | FPR2 | P25090 | 3/20 | 0.51 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.49 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.48 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.48 |
| ▸ | TP53BP1 | Q12888 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14158944 | 0.93 | ALDH1A1 (0.57) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL3523655 | 0.90 | TDP1 (0.60) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL17623630 | 0.87 | L3MBTL1 (0.57) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL17623638 | 0.87 | ESRRG (0.57) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL17623598 | 0.87 | ALDH1A1 (0.51) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL24920365 | 0.87 | ALDH1A1 (0.51) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL3758446 | 0.86 | ESRRG (0.53) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL6378393 | 0.86 | NPC1 (0.52) | NPC1ALDH1A1RAB9AKMT2AMEN1 | |
| SCHEMBL1467340 | 0.85 | NAAA (0.56) | NPC1ALDH1A1RAB9AHPGDKMT2A | |
| SCHEMBL1760150 | 0.84 | HDAC1 (0.49) | NPC1ALDH1A1RAB9AHPGDKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4434522-A2 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2024-09-25 | — | — | EP | disclosed |
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2024-05-09 | — | — | US | disclosed |
| EP-4277895-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | The United States of America, as represented by the Secretary, Department of Health and Human Services (US) | 2023-11-22 | — | — | EP | disclosed |
| CN-116964034-A | Heterocyclic ring P2Y 14 Receptor antagonists | 美国卫生和人力服务部 | 2023-10-27 | — | — | CN | disclosed |
| WO-2022155037-A1 | HETEROCYCLIC P2Y 14 RECEPTOR ANTAGONISTS | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2022-07-21 | — | — | WO | disclosed |
| WO-2019013789-A1 | ANTIMICROBIAL COMPOUNDS | CURZA GLOBAL, LLC (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240150290-A1 | HETEROCYCLIC P2Y14 RECEPTOR ANTAGONISTS | P2RY14, P2RY1, P2RY11 | NPC1 3576/4885ALDH1A1 2984/4885RAB9A 1333/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.